ArticleCureus2025
Primary Signet Ring Cell Carcinoma of the Lung: A Rare Histologic Variant With Distinct Radiologic Presentation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Signet ring cell carcinoma (SRCC) is a rare and distinct subtype of adenocarcinoma. It can arise in various organs, including the stomach, colon, breast, bladder, and prostate. It may also occur as a primary pulmonary tumor. We report a case of a 65-year-old woman with no significant medical history, who presented with a two-month history of dyspnea and hemoptysis, associated with weight loss. A chest CT scan revealed a locally advanced pulmonary mass with mediastinal lymphadenopathy and bilateral pulmonary metastases. A biopsy was performed and confirmed a diagnosis of pulmonary-origin signet ring cell adenocarcinoma. Given the patient's general condition, chemotherapy with weekly paclitaxel and carboplatin (AUC2) was initiated. At the first evaluation after three cycles, the disease was stable. The patient subsequently developed a respiratory infection due to a multidrug-resistant organism, and despite appropriate antibiotic therapy, she passed away because of the infection. Primary SRCC of the lung remains a diagnostic and therapeutic challenge, with poor prognosis despite early intervention. The rapid clinical decline observed in this case highlights the aggressive nature of the disease and the importance of supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.